CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention

OBJECTIVE: To study the use of CYP2C19 genotyping to guide P2Y(12) inhibitor selection to maximize efficacy, and attenuate risk in appropriate patients who underwent PCI for CAD. METHODS: We performed a retrospective analysis of 868 patients with CAD who received CYP2C19 genotyping after PCI and cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Stys, Tomasz P., Gedela, Maheedhar, Gowda, Smitha N., Bares, Valerie, Fanta, Lauren, Petrasko, Marian, Hajek, Catherine, Larson, Eric, Stys, Adam T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322803/
https://www.ncbi.nlm.nih.gov/pubmed/34154743
http://dx.doi.org/10.1016/j.ihj.2021.03.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322803/
https://www.ncbi.nlm.nih.gov/pubmed/34154743
http://dx.doi.org/10.1016/j.ihj.2021.03.004

Ejemplares similares